BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15677533)

  • 1. Imprinting, expression, and localisation of DLK1 in Wilms tumours.
    Fukuzawa R; Heathcott RW; Morison IM; Reeve AE
    J Clin Pathol; 2005 Feb; 58(2):145-50. PubMed ID: 15677533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
    Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
    Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
    Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
    J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imprinting status of DLK1 gene in brain tumors and lymphomas.
    Yin D; Xie D; De Vos S; Liu G; Miller CW; Black KL; Koeffler HP
    Int J Oncol; 2004 Apr; 24(4):1011-5. PubMed ID: 15010842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of imprinted genes in Wilms tumors.
    Hubertus J; Lacher M; Rottenkolber M; Müller-Höcker J; Berger M; Stehr M; von Schweinitz D; Kappler R
    Oncol Rep; 2011 Mar; 25(3):817-23. PubMed ID: 21174059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour.
    Steenman MJ; Rainier S; Dobry CJ; Grundy P; Horon IL; Feinberg AP
    Nat Genet; 1994 Jul; 7(3):433-9. PubMed ID: 7920665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19.
    Douc-Rasy S; Barrois M; Fogel S; Ahomadegbe JC; Stéhelin D; Coll J; Riou G
    Oncogene; 1996 Jan; 12(2):423-30. PubMed ID: 8570220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relaxation of IGF2 imprinting in Wilms tumours associated with specific changes in IGF2 methylation.
    Sullivan MJ; Taniguchi T; Jhee A; Kerr N; Reeve AE
    Oncogene; 1999 Dec; 18(52):7527-34. PubMed ID: 10602511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor.
    Ravenel JD; Broman KW; Perlman EJ; Niemitz EL; Jayawardena TM; Bell DW; Haber DA; Uejima H; Feinberg AP
    J Natl Cancer Inst; 2001 Nov; 93(22):1698-703. PubMed ID: 11717330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of genomic imprinting in Wilms' tumour and overgrowth disorders.
    Reeve AE
    Med Pediatr Oncol; 1996 Nov; 27(5):470-5. PubMed ID: 8827076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
    Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
    Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
    Fukuzawa R; Heathcott RW; More HE; Reeve AE
    J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic differences between Wilms' tumours in white and east-Asian children.
    Fukuzawa R; Breslow NE; Morison IM; Dwyer P; Kusafuka T; Kobayashi Y; Becroft DM; Beckwith JB; Perlman EJ; Reeve AE
    Lancet; 2004 Feb; 363(9407):446-51. PubMed ID: 14962525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic imprinting and Wilms' tumor.
    Moulton T; Chung WY; Yuan L; Hensle T; Waber P; Nisen P; Tycko B
    Med Pediatr Oncol; 1996 Nov; 27(5):476-83. PubMed ID: 8827077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
    Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor.
    Xu YQ; Grundy P; Polychronakos C
    Oncogene; 1997 Mar; 14(9):1041-6. PubMed ID: 9070652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors.
    Bjornsson HT; Brown LJ; Fallin MD; Rongione MA; Bibikova M; Wickham E; Fan JB; Feinberg AP
    J Natl Cancer Inst; 2007 Aug; 99(16):1270-3. PubMed ID: 17686827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor.
    Vu TH; Chuyen NV; Li T; Hoffman AR
    Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.